/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. The Foster City, California-based company develops drugs for the treatment of human immunodeficiency virus, liver diseases, haematology/oncology diseases, and inflammation/respiratory diseases.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and GILD fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company is best known for its HIV and hepatitis C therapies, including Biktarvy, Truvada, and Harvoni. The company also has a growing presence in oncology and cell therapy. Its strong R&D pipeline, global market reach, and focus on innovative treatments distinguish it from others.
